GYRE
NASDAQ HEALTHCAREGyre Therapeutics Inc.
$7.00
-$0.33 (-4.50%)
Live quote
52w: $5.44 – $9.42
Loading chart…
P/E Ratio82.73
P/B Ratio7.57
EV/EBITDA—
Debt/Equity—
ROE9.15%
ROIC—
Revenue Growth10.24%
Gross Margin87.38%
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary platform that harmoniously combines gene therapy with precision medicine, Gyre is focused on delivering innovative solutions to address significant unmet medical needs. With a robust pipeline and a strong commitment to scientific excellence, the company is well-positioned for sustained growth and impact in the biopharmaceutical sector. Its strategic collaborations and ongoing research and development efforts underscore Gyre's potential to revolutionize treatment paradigms and improve patient outcomes in challenging health conditions.
Own GYRE? Track it here.
Create a free account to add GYRE to a portfolio and watch your P/L update in real time.
Custom screens, valuation models and backtesting are coming to Pro.